Expression levels of TPX2 are increased in a variety of cancers (99–102) and we found that TPX2 gene expression levels are elevated in breast and ovarian cancers with pathogenic BRCA mutations compared to BRCA wild-type cancers. This evidence concerns the gene TPX2 and ovarian carcinoma.